Integrative OUD Care Techniques With Chiropractic Rehabilitation

Transform your recovery with integrative OUD care and chiropractic rehabilitation focused on whole-body healing.

Abstract

In this educational post, I present a comprehensive, first-person, clinician-centered exploration of opioid use disorder (OUD) care in complex populations, integrating the latest evidence from leading researchers with my clinical experience in a multidisciplinary practice. I walk you through:

• The intersection of OUD with co-occurring mental health disorders (major depressive disorder, anxiety disorders, PTSD), including screening, trauma-informed care, and pharmacologic/psychotherapeutic interventions.
• Considerations for OUD treatment during pregnancy, emphasizing neonatal outcomes, neonatal opioid withdrawal syndrome assessment, breastfeeding guidance, and medication-assisted treatment (MAT/MOUD) strategies using buprenorphine and methadone.
• Adolescent OUD care, including validated screening, harm-reduction, family engagement, school-based resources, and age-appropriate MOUD.
• OUD in older adults, with renal/hepatic dose adjustments, QTc safety, and CNS depressant co-prescribing.
• Management strategies when patients use benzodiazepines and other CNS depressants, guided by FDA safety communications and risk-benefit reasoning.

I also detail how we integrate chiropractic and functional medicine within Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, where I collaborate closely with our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933). Together, we combine internal medicine oversight, functional medicine, personal injury care, rehabilitation, and integrative chiropractic care to support whole-person recovery. Throughout, I emphasize physiological mechanisms, practical clinical pathways, and my observations from practice and published work, with citations to recent evidence.

About Our Integrative Team-Based Model in El Paso, Texas

I practice at Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas. Our clinic is built on a multidisciplinary framework common to integrative and injury care settings, where an MD provides medical direction alongside a chiropractor to ensure comprehensive, coordinated care.

• I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. My scope blends chiropractic, nursing, family practice, and functional medicine, enabling spine-focused musculoskeletal care integrated with systems biology, nutrition, lifestyle therapeutics, and pain science.
• Our Medical Director and Collaborative Physician is Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), an internist with over 40 years of experience. Dr. Cardenas provides medical oversight, ensuring internal medicine standards of care, medication safety (including MOUD), and coordination with OB, psychiatry, pediatrics/adolescents, and cardiology when needed.

How we work together:

• Cardenas evaluates medical comorbidities, prescribes/oversees MOUD (methadone if indicated via external OTP coordination or buprenorphine/naltrexone per guideline), coordinates lab testing, ECG monitoring for QTc, and ensures safety in pregnancy, adolescence, and older adults.
• I guide integrative chiropractic care to address pain generators (axial spine, sacroiliac joint, myofascial dysfunction), nervous system dysregulation (autonomic hyperarousal), posture and movement deficits, and injury rehabilitation, while incorporating functional medicine strategies (nutrition, sleep, stress resiliency, microbiome-aware care) to reduce the allostatic load that drives relapse risk.
• Our rehab team provides graded activity, motor control, and return-to-function programs; behavioral health partners provide CBT, trauma-focused therapies, and recovery coaching.
• We apply trauma-informed care, harm reduction, and shared decision-making, with access to naloxone training, peer support, and telehealth check-ins.

This integrated model aligns with evidence that blended medical, behavioral, and rehabilitative approaches increase treatment retention, reduce overdose risk, and improve long-term function (Volkow et al., 2019; Wakeman & Barnett, 2018).

Co-Occurring Mental Health Disorders and Opioid Use Disorder: An Integrated Clinical Pathway

Key Epidemiology and Clinical Implications

• According to the 2022 SAMHSA National Survey on Drug Use and Health, approximately 21.5 million U.S. adults live with co-occurring mental health and substance use disorders, yet only about 60% receive treatment for one disorder and 40% receive none (Substance Abuse and Mental Health Services Administration [SAMHSA], 2023).
• In OUD, rates of major depressive disorder, anxiety disorders, and PTSD are strikingly high, with MDD up to ~50%, anxiety ~30%, and PTSD ~20% in various cohorts (Davis et al., 2021; Kessler et al., 2005; Santucci, 2012).

Clinical significance:

• Depressive and anxious symptom clusters intensify pain, impair executive function, and increase relapse risk via amygdala-prefrontal circuit dysregulation; chronic opioid exposure further modifies reward and stress systems (Koob & Schulkin, 2019).
• PTSD intersects with OUD through hyperarousal, avoidance, and negative affect, driving self-medication cycles.

Screening and Measurement-Based Care

We implement routine, validated tools at intake and follow-up:

• PHQ-9 for depression severity; GAD-7 for anxiety severity (Kroenke et al., 2001; Spitzer et al., 2006).
• PCL-5 for PTSD symptomatology aligned with DSM-5: 20 items over the past month; scores ≥31–33 suggest probable PTSD and warrant further evaluation; a 10-point reduction indicates meaningful clinical response (Blevins et al., 2015; Weathers et al., 2013).

Why these tools:

• They standardize assessment, enable measurement-based care, and correlate with functional status and relapse risk. In my clinic, we use them to titrate psychotherapy intensity and guide SSRI/SNRI selections, documenting outcomes to reinforce shared decision-making.

Trauma-Informed Care: Foundational Principles

We embed six core principles in every patient touchpoint (SAMHSA, 2014):

• Safety: Physical and emotional environment that reduces threat; predictability in scheduling and care plans.
• Trustworthiness and transparency: Clear communication; no “surprise contingencies.”
• Peer support: Recovery groups and peer navigators to build hope and model recovery behaviors.
• Collaboration and mutuality: Patients as active partners; co-create goals and pacing.
• Empowerment, voice, and choice: Multiple options for therapy, medications, and body-based modalities.
• Cultural, historical, gender sensitivity: Tailor care to lived experiences, recognizing structural inequities.

Why it matters:

• Trauma-informed care reduces autonomic hypervigilance and strengthens the therapeutic alliance, a key predictor of treatment retention and outcomes in OUD (van der Kolk, 2014; Haskell et al., 2020).

Evidence-Based Psychotherapies

• For depression and anxiety, we emphasize cognitive behavioral therapy (CBT) and behavioral activation—modulating negative automatic thoughts, catastrophizing, avoidance, and promoting value-driven activities (Cuijpers et al., 2016).
• For PTSD, we refer for prolonged exposure (PE), cognitive processing therapy (CPT), or EMDR, which demonstrate efficacy in trauma syndromes with SUD comorbidity when coordinated with MOUD (Watts et al., 2013; Shapiro, 2017).

How chiropractic integrates:

• Pain amplifies depressive/anxious loops via central sensitization. Our chiropractic adjustments, myofascial release, neuromuscular re-education, and graded exercise modulate nociceptive drive and improve descending inhibitory pathways, lowering pain catastrophizing and reducing the drive for nonmedical opioid use (Busch et al., 2011). Autonomic-calming strategies (diaphragmatic breathing, vagal toning) complement CBT and exposure therapies by reducing sympathetic overactivity.

Pharmacotherapy: SSRIs/SNRIs With MOUD

First-line medications for MDD/GAD/PTSD include SSRIs and SNRIs (APA, 2020; VA/DoD, 2023). We match agents to patient profiles and MOUD:

• Paroxetine (MDD/GAD/PTSD): Effective across conditions; higher rates of sexual dysfunction—consider if intolerable.
• Sertraline (MDD/PTSD): Can cause transient GI symptoms; beneficial for PTSD clusters.
• Fluoxetine (MDD): Long half-life supports adherence; caution in overdose risk contexts.
• Escitalopram (MDD/GAD): Usually well-tolerated; monitor for weight gain.
• Duloxetine (MDD/GAD): Favorable for neuropathic pain, with potentially lower sexual dysfunction burden.
• Venlafaxine (MDD/GAD): Effective for anxious depression; monitor blood pressure and QTc

Interactions and safety:

• Buprenorphine: Mild serotonergic properties; risk of serotonin syndrome is low but real—benefit of treating depression/anxiety often outweighs risk, and combined treatment improves OUD retention (Nunes & Levin, 2004). We educate patients on SHIVERS symptoms: shivering, hyperreflexia/myoclonus, increased temperature, vital sign changes, encephalopathy, restlessness, sweating.
• Methadone: Monitor QTc prolongation risk, especially with citalopram >40 mg or in adults >60. We obtain baseline ECGs, repeat after ~5 half-lives of any QTc-prolonging agent, and assess symptoms (palpitations, syncope). We watch thresholds of >450 ms (men) and >460 ms (women) as clinical flags (CredibleMeds; FDA safety information).
• Naltrexone: Carries warnings for depressed mood/suicidality; SSRIs/SNRIs also carry black box warnings in youth. We do not categorically avoid; we integrate close monitoring and safety planning when benefits exceed risks.

Case Application: 32-Year-Old Female With OUD, Depression, and Anxiety

• Profile: Chronic low back pain due to degenerative disc disease; maintained on buprenorphine-naloxone 8 mg TID; severe OUD history; PHQ-9=18 (moderate-severe); GAD-7=15 (severe); PCL-5=10 (no PTSD).
• Plan in our integrated model:

• • Continue buprenorphine-naloxone for stabilization and relapse prevention.
  • Initiate sertraline or duloxetine based on pain comorbidity and side-effect tolerability; monitor for serotonin syndrome, though risk is low.
  • Begin CBT with behavioral activation and worry exposure; integrate graded motor control, chiropractic adjustments for segmental dysfunction, and myofascial techniques to downregulate nociception and reduce pain catastrophizing.
  • Provide naloxone to the patient and family; safety plan with crisis resources (988 Lifeline).
  • Functional medicine support: Sleep hygiene, anti-inflammatory nutrition, and mindfulness-based stress reduction to rebalance HPA axis and improve recovery capital (discussed later).

Rationale:

• Treating the co-occurring depression/anxiety improves reward-system recovery, enhances prefrontal regulation, and increases MOUD retention, a powerful predictor of reduced mortality (Sordo et al., 2017).

Opioid Use Disorder and Pregnancy: Protecting Two Lives Through Integrated Care

Rising Prevalence and Clinical Burden

• OUD in pregnancy increased markedly between 1999 and 2014, with continued increases documented at delivery from 2010–2017; neonatal opioid withdrawal syndrome (NOWS) rose substantially, with a baby born with NOWS approximately every 24 minutes in 2021 (Hirai et al., 2021; Patrick et al., 2012; Ko et al., 2016; Winkelman et al., 2018).
• Rural regions often show higher rates, reflecting access disparities (Haight et al., 2018).

Addressing Stigma and Access

• Pregnant patients with OUD face profound stigma, often judged as “unfit” or “drug-seeking,” which contributes to care avoidance and risk of overdose (Fitzgerald & Hurst, 2017). Our team counters this with nonjudgmental, trauma-informed, and family-centered care, prioritizing universal screening and immediate engagement in treatment.

Universal Screening in Pregnancy

Validated tools we use in coordination with OB partners:

• Four Ps: Parents, Partner, Past, Present—yes to any prompts warrants a deeper assessment (Chasnoff et al., 2007).
• NIDA Quick Screen: Identifies past-year use across substances; positive screens lead to detailed assessments (NIDA, 2023).
• CRAFFT for younger pregnant patients (<27 years), assessing risky behaviors (Knight et al., 2002).

Why universal:

• Selective screening misses many patients and perpetuates bias. Consistent screening improves early detection and timely initiation of MOUD, which enhances maternal and neonatal outcomes (ACOG, 2017; SAMHSA, 2018).

Maternal and Fetal Risks Without Treatment

• Cycles of use and withdrawal lead to placental insufficiency, abruption, fetal growth restriction, preterm birth, and stillbirth; overdose remains a leading cause of maternal mortality (Hollander et al., 2023). Regular prenatal care is often inconsistent without supportive engagement.

Neonatal Opioid Withdrawal Syndrome (NOWS)

• Babies cannot be “addicted” per DSM-5—addiction requires behavioral criteria; neonates experience withdrawal, not addiction (APA, 2013).
• Symptoms: Tremors, excessive crying, poor feeding, fever, diarrhea, vomiting, sleep dysregulation.
• Assessments:

• • Eat, Sleep, Console (ESC): Simplified functional assessment—can baby eat ≥1 oz/feed, sleep ≥1 hr, be consoled within 10 minutes? ESC-based care reduces pharmacologic exposure and length of stay (Grossman et al., 2018).
  • Finnegan Scoring System: Detailed 21-item symptom checklist, used in some hospitals.

• Course: Symptoms last days to weeks depending on exposure; rooming-in, breastfeeding support, swaddling, and skin-to-skin are first-line nonpharmacologic care.

Breastfeeding Guidance

• Benefits: Reduced infections, SIDS, maternal cancer risk, postpartum depression; enhanced bonding and stress reduction (Victora et al., 2016).
• Breastfeeding is generally encouraged for mothers on buprenorphine or methadone when stable and without contraindications (ACOG, 2017).
• Contraindications: Ongoing nonprescribed opioid use, certain infections (e.g., HIV in high-resource settings per local guidance), or incompatible medications.

Medications for OUD in Pregnancy

• Buprenorphine and methadone are first-line and improve maternal and neonatal outcomes; ACOG, SAMHSA, and WHO endorse them (ACOG, 2017; WHO, 2014; SAMHSA, 2018).
• Naltrexone is not first-line but not absolutely contraindicated; shared decision-making is crucial given limited pregnancy data.
• Medically assisted withdrawal (detox) is not recommended due to high relapse and overdose risk.
• Neonatal outcomes: MOUD is associated with a higher likelihood of term birth and normal birth weight; not all infants experience NOWS, but observation for 72–96 hours is prudent.

How our clinic coordinates:

• Cardenas co-manages MOUD with OB, ensuring safe dose titration, ECG if methadone exposure is relevant, and tight prenatal integration.
• I support musculoskeletal care for pregnancy-related pain (pelvic girdle, lumbar spine), using gentle, pregnancy-appropriate chiropractic techniques, pelvic floor-aware rehab, and breathwork to reduce pain and stress without opioids.
• Functional medicine: We emphasize nutrient-dense prenatal nutrition, glycemic balance, iron and choline adequacy, and sleep optimization, which support fetal development and maternal resilience.

Pregnancy Case Application

• 28-year-old, G2P1 at 18 weeks; daily oxycodone ER ~60 mg; anxious, motivated to stop; labs normal.
• Plan:

• • Begin buprenorphine induction 24 hours after last oxycodone dose; titrate from 2 mg up to clinical stabilization (frequently up to 16–24 mg).
  • Coordinate with prenatal care and provide naloxone
  • Initiate psychosocial support and gentle movement/rehab to address pain and stress.
  • Encourage breastfeeding postpartum if no contraindications; implement ESC-informed neonatal care with the hospital team.

Rationale:

• Buprenorphine in pregnancy reduces illicit use, stabilizes maternal physiology, and lowers risk of obstetric complications; nonpharmacologic neonatal care reduces need for morphine.

Adolescent Opioid Use Disorder: Early Identification and Age-Appropriate Treatment

Rapidly Changing Risk Landscape

• From 2019 to 2020, overdose deaths increased by 94% in 14–18-year-olds; another 20% increase from 2020 to 2021. Use rates fell, but potency and contamination (e.g., illicitly manufactured fentanyl) surged; IMF-involved deaths rose by 183% (CDC, 2022; Friedman et al., 2022).
• Many decedents had mental health histories; few had received OUD treatment.

Protective and Risk Factors

• Protective: Family engagement, guardian disapproval of substance use, school connectedness, self-efficacy.
• Risk: Adverse social determinants, early initiation, polysubstance use, impulsivity, psychiatric disorders, maltreatment, and family SUD history (NIDA, 2020).

Confidential Screening and One-on-One Counseling

• Explain confidentiality upfront per state laws to maintain trust. Always reserve private time with the adolescent to discuss sensitive topics and provide harm-reduction education.

Validated tools:

• S2BI (Screening to Brief Intervention): Frequencies of use across substances over the past year (Levy et al., 2016).
• BSTAD (Brief Screener for Tobacco, Alcohol, and other Drugs): Days used and substance categories.
• CRAFFT: Behavioral risk and functional impairment signals; ≥2 positives prompt further assessment (Knight et al., 2002).

Treatment Recommendations

• Naloxone access and training for youth, family, and peers; develop plans for high-risk scenarios (parties, new social settings).
• Behavioral health: CBT, family-based therapy (e.g., multidimensional family therapy), school-based counseling, and peer recovery supports.
• MOUD:

• • Buprenorphine is approved for adolescents aged ≥16 with moderate to severe OUD.
  • Methadone and naltrexone are typically approved for ≥18; we follow evolving guidance (ASAM adolescent updates anticipated in 2026).

• Integrative care:

• • Address post-injury pain drivers (e.g., ankle surgery sequelae) with chiropractic, rehab, and pain neuroscience education to reduce the perceived need for opioids.
  • Family coaching on communication, boundaries, and monitoring balances autonomy and safety.

Adolescent Case Application

• 16-year-old female, prior ankle ORIF; progressed from leftover oxycodone to heroin over 6 months; presents drowsy and nauseated; UDS positive for heroin, negative for fentanyl and other substances.
• Plan:

• • Initiate buprenorphine 12–24 hours after last heroin use; titrate 2 mg upward to stabilization.
  • Provide naloxone and harm-reduction education about fentanyl contamination risk.
  • Connect to adolescent-informed psychotherapy, family therapy, and school supports.
  • Chiropractic/rehab to address residual ankle mechanics, kinetic chain deficits, core stability, and return-to-sport progression to rebuild identity and self-efficacy—powerful protective factors.

Rationale:

• Early, developmentally attuned MOUD plus family-school engagement improves retention and curbs overdose risk; orthopedic recovery reduces pain triggers that can drive relapse.

OUD in Older Adults: Pharmacology, Physiology, and Practical Safety

Epidemiology and Disparities

• Since 2013, OUD has tripled among adults 65–69, with higher prevalence in Medicare and Medicaid populations; increased vulnerability documented among Black Americans, Native Americans, and Alaska Natives (Han et al., 2017; Davis et al., 2021).

Age-Related Considerations

• Pharmacokinetics: Reduced renal/hepatic clearance alters opioid metabolism; polypharmacy increases interaction risk.
• Methadone:

• • Consider dose reduction if creatinine clearance <10 mL/min by 50–75% and titrate carefully.
  • Evaluate QTc at baseline and periodically; be cautious with concomitant QTc-prolonging agents (e.g., certain SSRIs, antipsychotics).
  • Higher risk for respiratory depression due to full agonism and variable clearance.

• Buprenorphine:

• • Less impact from renal impairment; consider dose adjustments for severe hepatic impairment.
  • Avoid certain long-acting injectable formulations with moderate-to-severe liver disease per labeling.

• Monitoring:

• • We follow closer clinical reviews, medication reconciliation for interactions (e.g., CYP3A4 inhibitors/inducers), orthostatic vitals, falls risk assessment, and ECGs when warranted.

Integrative strategies:

• For chronic pain common in older adults (spinal stenosis, osteoarthritis, myofascial pain), chiropractic, flexion-distraction, gentle mobilization, balance training, and sarcopenia-focused resistance work safely improve function and reduce reliance on analgesics.
• Nutrition: Protein adequacy, vitamin D, omega-3s, and addressing sarcopenic obesity support neuroplasticity and analgesic responsiveness.

Managing OUD With Concurrent Benzodiazepines and CNS Depressants

Risk-Benefit Balancing Guided by FDA Safety Communications

• The FDA urges caution against withholding MOUD when patients are taking benzodiazepines or CNS depressants; risks of untreated OUD often exceed additive respiratory depression risks (FDA, 2017).
• Key points:

• • Not a contraindication to MOUD.
  • Avoid arbitrary MOUD dose caps based solely on benzo co-use.
  • Provide patient education about additive sedation and overdose risk; co-prescribe naloxone.
  • When possible, taper benzodiazepines gradually while transitioning anxiety treatment to SSRIs/SNRIs and psychotherapy.

CNS depressants to consider:

• Benzodiazepines (e.g., alprazolam, clonazepam).
• Sedative-hypnotics (zolpidem, eszopiclone).
• Muscle relaxants (baclofen, carisoprodol).
• Antipsychotics (quetiapine, olanzapine) as sedating co-agents.
• Gabapentinoids (gabapentin, pregabalin) can compound sedation.

Clinical process:

• Cardenas conducts a comprehensive medication review, screens for sleep apnea and pulmonary disease, and adjusts dosages or schedules (e.g., nighttime dosing of sedatives when appropriate, avoiding alcohol).
• Our team introduces nonpharmacologic anxiety and sleep interventions: CBT-I, stimulus control, sleep compression, bright light therapy, breathing protocols, and chiropractic strategies to reduce muscle tension and pain that perpetuate insomnia.

Pain Science, Neurobiology, and Why Integrative Chiropractic Care Matters in OUD

The Pain-OUD Reciprocity

• Chronic pain augments negative affect, reward dysregulation, and avoidance, fueling opioid misuse. Opioids transiently reduce pain but sensitize reward thresholds and dysregulate stress systems (Koob & Volkow, 2016).
• Central sensitization heightens pain perception; maladaptive cortical maps in motor/somatosensory regions perpetuate movement-related fear and pain persistence.

Mechanisms Leveraged by Integrative Care

• Chiropractic adjustments and manual therapy influence mechanoreceptor input at joint capsules and paraspinals, potentially enhancing descending inhibitory control and reducing nociceptive drive. Studies support multimodal nonpharmacologic care for spinal pain and reduced opioid exposure (Qaseem et al., 2017; Kazis et al., 2019).
• Myofascial release, trigger point therapy, and neuromuscular re-education normalize tone and improve proprioception; reduced myofascial nociception lowers central arousal.
• Graded exposure and exercise recalibrate threat appraisal and improve cortical body maps, decreasing kinesiophobia and relapse risk.
• Breathwork and vagal toning (paced respiration, resonance breathing) dampen sympathetic dominance and improve interoceptive awareness, aligning with trauma-informed

Functional Medicine Supports Recovery Capital

• Nutrition: Anti-inflammatory dietary patterns, omega-3 fatty acids, magnesium, and micronutrients support synaptic plasticity and neurotransmitter balance; stable glycemia reduces mood volatility.
• Sleep: Prioritizing circadian regularity and CBT-I enhances prefrontal control over limbic reactivity; sleep loss strongly triggers cravings.
• Stress/Trauma: Mindfulness, somatic experiencing, and movement therapies expand a window of tolerance and reduce relapse risk by improving emotion regulation.

My clinical observations (see WellnessDoctorRx.com and LinkedIn) consistently show that aligning musculoskeletal correction with metabolic and behavioral stabilization improves pain control, increases activity engagement, and supports more durable OUD recovery trajectories.

Enhancing Health Together: Embracing Multidisciplinary Evaluation and Treatment- Video

Implementation Blueprint: How We Integrate MOUD, Medical Oversight, Chiropractic, and Rehab

Intake and Assessment

• Medical evaluation by Dr. Cardenas:

• • Confirm OUD diagnosis, assess for co-occurring disorders, review meds, labs (CBC, CMP, LFTs), infectious disease screening (HIV, hepatitis), pregnancy testing when indicated.
  • ECG for QTc if methadone is used or QT-prolonging meds are present.

• Behavioral health screening:

• • PHQ-9, GAD-7, PCL-5, substance use tools (S2BI, BSTAD, CRAFFT for youth).

• Functional and pain assessment:

• • Regional exam, movement screen, posture, gait, palpation for myofascial dysfunction, joint restrictions.

Shared Decision-Making and Care Planning

• Discuss MOUD options: buprenorphine, methadone (with OTP coordination), naltrexone when appropriate.
• Align psychotherapy with symptom profiles (CBT for depression/anxiety, trauma-focused for PTSD).
• Introduce chiropractic/rehab plan:

• • Frequency, goals, and graded activity
  • Self-management: home exercise programs, ergonomics, sleep, and stress strategies.

Safety and Harm Reduction

• Naloxone distribution and training for patient and family.
• Education about fentanyl contamination, test strips where permissible, and safer-use practices for those at risk.
• Crisis planning with 988 and community supports.

Follow-Up and Measurement-Based Adjustments

• Regular visits to titrate MOUD, monitor side effects, repeat PHQ-9/GAD-7/PCL-5 to quantify response.
• Rehab progression: adjust exercise intensity, incorporate return-to-work or sport planning.
• Periodic ECG if indicated; monitor metabolic parameters if antipsychotics or other risk agents are used.

Coordination of Care

• Seamless referrals to OB, psychiatry, cardiology, hepatology, or sleep medicine as appropriate.
• Communication with schools, family, and legal advocates (with consent), especially for adolescents and injury cases.

Practical Pearls Across Special Populations

• Co-occurring disorders:

• • Treat depression/anxiety/PTSD alongside OUD—combined care improves retention and outcomes.
  • Balance serotonergic safety with clinical benefit; educate on serotonin syndrome.

• Pregnancy:

• • Prefer buprenorphine or methadone over withdrawal; coordinate prenatal care; encourage breastfeeding with stability.
  • Use ESC to minimize neonatal pharmacotherapy when possible.

• Adolescents:

• • Prioritize confidentiality, family engagement, and school supports.
  • Use buprenorphine for ≥16 years when indicated; normalize naloxone in the home.

• Older adults:

• • Adjust for renal/hepatic function; monitor QTc with methadone; reduce fall risk; integrate gentle, function-focused rehab.

• Benzodiazepines/CNS depressants:

• • Do not withhold MOUD solely due to benzo use; taper when possible; enhance nonpharmacologic anxiety and sleep care.

Why This Integrated Model Works

• OUD is a biopsychosocial condition: pharmacology alone is necessary but insufficient for durable recovery.
• By combining medical stabilization (MOUD) with pain-focused chiropractic, movement rehabilitation, functional medicine, and evidence-based psychotherapy, we reduce the biological, psychological, and social drivers of relapse.
• Our collaboration—anchored by Dr. Cardenas’s internal medicine leadership and my integrative chiropractic and functional medicine approach—creates a safety net where each modality amplifies the others, improving adherence, function, and quality of life.

For ongoing clinical insights, protocols, and case reflections, you can visit my resources at WellnessDoctorRx.com and my professional updates on LinkedIn.

References

• American College of Obstetricians and Gynecologists. (2017). Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711.
• American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.).
• American Psychiatric Association. (2020). Practice guideline for the treatment of patients with major depressive disorder.
• Blevins, C. A., et al. (2015). The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5). Psychological Assessment.
• Centers for Disease Control and Prevention. (2022). Adolescent overdose deaths involving illicitly manufactured fentanyl.
• Chasnoff, I. J., et al. (2007). The4P’ss Plus screen for substance use in pregnancy. Obstetrics & Gynecology.
• Cuijpers, P., et al. (2016). CBT for depression: A meta-analysis. Journal of Affective Disorders.
• Davis, C. S., et al. (2021). Opioid use disorder and mental health comorbidities. JAMA.
• Food and Drug Administration. (2017). FDA Drug Safety Communication: Risks from combining opioid addiction medicines with benzodiazepines.
• Friedman, J., et al. (2022). Fentanyl and adolescent overdose. JAMA.
• Grossman, M. R., et al. (2018). A novel approach to neonatal abstinence syndrome: ESC. Pediatrics.
• Haight, S. C., et al. (2018). Opioid use disorder documented at delivery. MMWR.
• Han, B., et al. (2017). Opioid misuse in older adults. American Journal of Public Health.
• Hirai, A. H., et al. (2021). Neonatal abstinence syndrome trends. JAMA Pediatrics.
• Haskell, S. G., et al. (2020). Trauma-informed care in substance use treatment. Journal of Substance Abuse Treatment.
• Kazis, L. E., et al. (2019). Chiropractic care and opioid use in soldiers with back pain. JAMA Internal Medicine.
• Kessler, R. C., et al. (2005). Lifetime prevalence of mental disorders. Archives of General Psychiatry.
• Knight, J. R., et al. (2002). CRAFFT development and validation. Pediatrics.
• Ko, J. Y., et al. (2016). Incidence of NAS. Pediatrics.
• Koob, G. F., & Schulkin, J. (2019). Addiction and stress systems. Neuroscience & Biobehavioral Reviews.
• Koob, G. F., & Volkow, N. D. (2016). Neurobiology of addiction. Neuropsychopharmacology.
• Kroenke, K., et al. (2001). The PHQ-9. Journal of General Internal Medicine.
• Levy, S., et al. (2016). S2BI. Pediatrics.
• National Institute on Drug Abuse. (2020). Principles of adolescent substance use disorder treatment.
• National Institute on Drug Abuse. (2023). NIDA Quick Screen.
• Nunes, E. V., & Levin, F. R. (2004). Treatment of depression in patients with alcohol or other drug dependence. American Journal of Psychiatry.
• Patrick, S. W., et al. (2012). NAS and hospital charges. JAMA.
• Qaseem, A., et al. (2017). Noninvasive treatments for acute, subacute, and chronic low back pain. Annals of Internal Medicine.
• Santucci, K. (2012). Substance misuse and mental health comorbidity. Pediatrics.
• Shapiro, F. (2017). Eye movement desensitization and reprocessing. Guilford.
• Sordo, L., et al. (2017). Mortality risk during and after opioid substitution treatment. BMJ.
• Spitzer, R. L., et al. (2006). GAD-7. Archives of Internal Medicine.
• Substance Abuse and Mental Health Services Administration. (2014). SAMHSA’s Concept of Trauma and Guidance for a Trauma-Informed Approach.
• Substance Abuse and Mental Health Services Administration. (2018). Clinical guidance for treating pregnant and parenting women with OUD.
• Substance Abuse and Mental Health Services Administration. (2023). Key substance use and mental health indicators in the United States: Results from the 2022 NSDUH.
• S. Department of Veterans Affairs & Department of Defense. (2023). VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder.
• van der Kolk, B. (2014). The body keeps the score.
• Victora, C. G., et al. (2016). Breastfeeding 21st-century benefits. The Lancet.
• Wakeman, S. E., & Barnett, M. L. (2018). Primary care and OUD treatment. New England Journal of Medicine.
• Watts, B. V., et al. (2013). Meta-analysis of psychotherapies for PTSD. Journal of Clinical Psychology.
• World Health Organization. (2014). Guidelines for the identification and management of substance use and substance use disorders in pregnancy.
• Winkelman, T. N. A., et al. (2018). NAS trends in the U.S. Pediatrics.

SEO tags: opioid use disorder, integrative chiropractic care, buprenorphine, methadone, naltrexone, pregnancy OUD, neonatal opioid withdrawal syndrome, Eat Sleep Console, adolescent OUD, benzodiazepines and MOUD, QTc monitoring, trauma-informed care, CBT, EMDR, functional medicine, chronic pain, central sensitization, El Paso Injury Medical Clinic, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, internal medicine oversight, personal injury rehabilitation